Gastric Cancer

Gastric and esophageal cancer treated by paclitaxel poliglumex and concurrent radiation

Published in Drug Week, October 27th, 2006

Gastric and esophageal cancer could be treated by paclitaxel poliglumex (PPX-xyotax) and concurrent radiation (RT) at a maximal tolerated dose (MTD) of 70 mg/m²/wk.

According to recent research published in the American Journal of Clinical Oncology - Cancer Clinical Trials, "[The study's aim was] to determine the MTD and dose limiting toxicities of poly(L-glutamic acid)-paclitaxel (PPX) and concurrent RT (PPX/RT) for patients with esophageal and gastric cancer. Patients with esophageal or gastric cancer receiving chemoradiation for loco-regional, adjuvant, or palliative intent were eligible. The initial dose of PPX was 40 mg/m²/wk, for 6...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry